Literature DB >> 14519553

Duplexes of 21-nucleotide RNAs mediate RNA interference in differentiated mouse ES cells.

Gang-Ming Zou1, Wei Wu, Jianjun Chen, Janet D Rowley.   

Abstract

RNA interference (RNAi) is a novel phenomenon that can induce post-transcriptional gene silencing (PTGS) both in animals and plants. RNAi is effective in suppressing specific gene expression in the early mouse embryonic cells and in undifferentiated embryonic stem (ES) cells. In this study, we demonstrate that dsRNA is effective in inducing PTGS in differentiated ES cells: CD34+ embryoid body (EB) cells, as confirmed by western blot and immunocytochemical staining. PU.1 is a key transcription factor in myeloid differentiation. Undifferentiated ES cells do not express PU.1; however it is expressed when ES cells differentiate into EBs. PU.1 could be suppressed by the specific PU.1 dsRNA, but not non-specific Lamin A/C dsRNA, in the CD34+ EB cells when they were induced to myeloid differentiation in the presence of GM-CSF and IL-3. As a consequence, the level of expression of CD115 (M-CSF receptor), one of the downstream genes regulated by PU.1 is decreased in PU.1 dsRNA treated CD34+ EB cells, but not in Lamin A/C dsRNA treated cells. To explore this phenomenon in other myeloid gene, we also found that C/EBPalpha gene could be knocked down by C/EBPalpha dsRNA. Our finding demonstrates that RNAi is effective in inhibiting specific gene expression in differentiated ES cells. RNAi offers a new methodology for study of hematopoietic regulation using ES cell differentiation.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14519553     DOI: 10.1016/s0248-4900(03)00079-0

Source DB:  PubMed          Journal:  Biol Cell        ISSN: 0248-4900            Impact factor:   4.458


  8 in total

1.  Integrin inhibition through Lyn-dependent cross talk from CXCR4 chemokine receptors in normal human CD34+ marrow cells.

Authors:  Yuji Nakata; Brian Tomkowicz; Alan M Gewirtz; Andrzej Ptasznik
Journal:  Blood       Date:  2006-02-07       Impact factor: 22.113

Review 2.  Application of RNA interference in treating human diseases.

Authors:  S Abdolhamid Angaji; Sara Sadate Hedayati; Reihane Hosein Poor; Safoura Madani; Sanaz Samad Poor; Samin Panahi
Journal:  J Genet       Date:  2010-12       Impact factor: 1.166

3.  Promoter cross-talk affects the inducible expression of intronic shRNAs from the tetracycline response element.

Authors:  Seong Kyun Park; Byung Joon Hwang; Yun Kee
Journal:  Genes Genomics       Date:  2019-01-17       Impact factor: 1.839

4.  O-fucose modulates Notch-controlled blood lineage commitment.

Authors:  Quanjian Yan; David Yao; Lebing L Wei; Yuanshuai Huang; Jay Myers; Lihua Zhang; Wei Xin; Jeongsup Shim; Yunfang Man; Bronislawa Petryniak; Stanton Gerson; John B Lowe; Lan Zhou
Journal:  Am J Pathol       Date:  2010-04-02       Impact factor: 4.307

5.  Knockdown of Pu.1 by small interfering RNA in CD34+ embryoid body cells derived from mouse ES cells turns cell fate determination to pro-B cells.

Authors:  Gang-Ming Zou; Jian-Jun Chen; Mervin C Yoder; Wei Wu; Janet D Rowley
Journal:  Proc Natl Acad Sci U S A       Date:  2005-09-01       Impact factor: 11.205

6.  Isolation and immunomodulatory activity of bursal peptide, a novel bursal peptide from the chicken bursa of Fabricius.

Authors:  Xiao-Dong Liu; Yingjuan Qian; Yong-Sam Jung; Pu-Yan Chen
Journal:  J Vet Sci       Date:  2015       Impact factor: 1.672

7.  Functionalized MoS2 Nanosheets as Multi-Gene Delivery Vehicles for In Vivo Pancreatic Cancer Therapy.

Authors:  Feng Yin; Tommy Anderson; Nishtha Panwar; Kang Zhang; Swee Chuan Tjin; Beng Koon Ng; Ho Sup Yoon; Junle Qu; Ken-Tye Yong
Journal:  Nanotheranostics       Date:  2018-08-25

Review 8.  Clinical Applications of Short Non-Coding RNA-Based Therapies in the Era of Precision Medicine.

Authors:  Ellen S Smith; Eric Whitty; Byunghee Yoo; Anna Moore; Lorenzo F Sempere; Zdravka Medarova
Journal:  Cancers (Basel)       Date:  2022-03-21       Impact factor: 6.575

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.